Henry Schein completes investment, names new board members
By HME News Staff
Updated 9:35 AM CDT, Mon May 19, 2025
MELVILLE, N.Y. - Henry Schein has announced the completion of a $250 million strategic investment by funds affiliated with KKR, making the investment firm a holder of about 12% of the common shares of the company, and the appointment of William K. “Dan” Daniel as an independent director. Daniel is an executive advisor to KKR and a former executive vice president of Danaher Corp. He joins Max Lin, partner at KKR and leader of the firm’s health care industry team in the Americas, who became a member of Henry Schein’s board on May 2. “We are pleased to welcome Max and Dan to the Board as we embark on this exciting next chapter for Henry Schein,” said Stanley M. Bergman, Chairman of the Board and Chief Executive Officer of Henry Schein. “Their deep experience in health care, operations, and strategic growth will be invaluable as we continue executing on our BOLD+1 strategy and creating long-term value for our stakeholders.” In connection with each of their appointments, Lin was appointed to the Nominating and Governance Committee as vice chair, and Daniel was appointed to the Compensation Committee. Both were appointed to the Strategic Advisory Committee.
-
Related: Henry Schein receives funding and advances bold plan.
Comments